Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » MRI-guided FUS Thalamotomy for Medically Refractory Parkinson’s Tremor
    ABSTRACT & COMMENTARY

    MRI-guided FUS Thalamotomy for Medically Refractory Parkinson’s Tremor

    December 1, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Deep Brain Stimulation (DBS) Is a safe and Effective Treatment for Medically Refractory Essential Tremor

    Quality of Life After Focused Ultrasound Thalamotomy in Parkinson’s Disease

    Precise Localization of Focused Ultrasound Thalamotomy Determines Clinical Benefit

    Related Products

    Functional MRI in REM Behavior Disorder Is Suggestive of Future Parkinson’s Disease

    Prevalence of Rest Tremor in Essential Tremor

    Keywords

    tremor

    parkinson’s

    thalamotomy

    By Harini Sarva, MD

    Assistant Professor of Clinical Neurology, Weill Cornell Medical College; Assistant Attending Neurologist, New York Presbyterian Hospital

    Dr. Sarva reports no financial relationships relevant to this field of study.

    SYNOPSIS: This study comparing 20 individuals who received MRI-guided focused ultrasound thalamotomy with seven individuals who received sham treatment showed improvements in Parkinson’s disease tremor. Side effects were similar to prior studies of this technology for essential tremor, with ataxia and limb/orofacial paresthesias being most common.

    SOURCE: Bond AE, Shah BB, Huss DS, et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson’s disease: A randomized clinical trial. JAMA Neurol 2017; Oct. 30. doi:10.1001/jamaneurol.2017.3098. 

    This was a randomized, sham-controlled pilot study to assess the safety and efficacy of MRI-guided focused ultrasound (FUS) thalamotomy for the treatment of medically refractory tremor in tremor-predominant Parkinson’s disease (PD). The patients were blinded for the first three months, after which those who received sham treatment were offered FUS. They were all followed unblinded for one year. All patients were prepared the same way. For the first three months, the patients and examiners were blinded. Those with tremor-predominant PD with severe, disabling, medication-refractory tremor were included. The FUS was planned and performed as in the previous essential tremor studies. The primary endpoint was a change in the Clinical Rating Scale for Tremor (CRST) Section A (assesses resting, postural, and action tremor) and Section B (assesses tremor while performing tasks such as handwriting) in the “on” medication state. Twenty-seven patients were enrolled, 20 in the treatment arm and seven in the sham procedure arm. The treated arm had a 62% reduction in the CRST scores from baseline whereas the sham arm had a 22% reduction from baseline. Secondary endpoints, such as improvements in the Unified Parkinson’s Disease Rating Scale, were greater in the thalamotomy arm as opposed to the sham group. Thalamotomy and procedure-related adverse events were noted. In the thalamotomy group, ataxia and limb and orofacial paresthesias were the most common. At the one-year mark, 19% had persistent paresthesia and 4% had ataxia. Two had mild, transient hemiparesis. The common procedure-related adverse events were headache and vertigo. All patients were available for the three-month follow-up but after unblinding, six of the seven who received sham treatment received the FUS thalamotomy. Six of the original 20 treated subjects did not have follow-up at one year. Of the six who later received the treatment after unblinding, two had very good tremor control, one had marginal control, and three had inadequate tremor control. Of the 14 of the original 20 from the treatment cohort, 13 reported a positive outcome.

    COMMENTARY

    Deep brain stimulation (DBS) has been an effective surgical treatment for PD motor symptoms for more than a decade. However, implantable hardware, insufficient numbers of neurologists with DBS programming experience, and the invasiveness of the surgery make FUS lesioning a promising option to treat medically refractory PD symptoms. For those who have cognitive or medical contraindications to DBS, FUS offers a means of improving quality of life. The rationale for lesioning the ventral intermedius nucleus (VIM) thalamus is clear, as the tremor circuitry in PD likely involves the dentato-rubro-thalamic tracts. However, while tremor can be treated by lesioning this target, remaining PD symptoms would not respond to thalamic lesioning. Subthalamic nucleus (STN) and globus pallidus interna (GPi) would be the preferred targets, and studies of those targets are required in PD. An important consideration is that FUS is still a lesioning procedure, and in PD, both sides would need to be treated to obtain adequate symptom control. However, lesioning of bilateral targets, GPi, STN, or VIM would lead to unwanted side effects (dysarthria, ataxia, corticospinal tract involvement).

    Thus, DBS remains a better option when bilateral surgical treatment is warranted. Another benefit of DBS over FUS is the use of electrophysiology in targeting the specific nuclei, but with the use of more advanced MRI technology such as tractography, visualization of the nuclei during FUS procedures is evolving. Despite the small sample size, this is still a promising study and opens the door for consideration of FUS in the treatment of PD, enabling better treatment of patients with medically refractory motor symptoms who cannot have DBS.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 4) - December 2017
    December 1, 2017

    Table Of Contents

    Treatment for Spinal Muscular Atrophy

    Neurologic Consequences of Zika Virus Infection

    MRI-guided FUS Thalamotomy for Medically Refractory Parkinson’s Tremor

    Optimizing Brain Oxygen in Severe Traumatic Brain Injury

    Systemic Immune Activation and the Course of Amyotrophic Lateral Sclerosis

    Neurologic Complications of Checkpoint Inhibitors

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: Neurology Alert’s editor in chief, Matthew Fink, MD, reports he is a consultant for Procter & Gamble. Peer reviewer M. Flint Beal, MD; executive editor Leslie Coplin; editor Jonathan Springston; and editorial group manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing